Epidemiology

You have full text access to this OnlineOpen article

C-reactive protein and colorectal cancer risk: A systematic review of prospective studies

  1. Konstantinos K. Tsilidis1,
  2. Casey Branchini2,
  3. Eliseo Guallar1,3,
  4. Kathy J. Helzlsouer1,4,5,6,
  5. Thomas P. Erlinger7,
  6. Elizabeth A. Platz1,6,†,*

Article first published online: 4 JUN 2008

DOI: 10.1002/ijc.23606

Issue

International Journal of Cancer

International Journal of Cancer

Volume 123, Issue 5, pages 1133–1140, 1 September 2008

Additional Information

How to Cite

Tsilidis, K. K., Branchini, C., Guallar, E., Helzlsouer, K. J., Erlinger, T. P. and Platz, E. A. (2008), C-reactive protein and colorectal cancer risk: A systematic review of prospective studies. Int. J. Cancer, 123: 1133–1140. doi: 10.1002/ijc.23606

Author Information

  1. 1

    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

  2. 2

    Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

  3. 3

    Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, MD

  4. 4

    George W. Comstock Center for Public Health Research and Prevention, Johns Hopkins Bloomberg School of Public Health, Hagerstown, MD

  5. 5

    Prevention and Research Center, Weinberg Center for Women's Health and Medicine, Mercy Medical Center, Baltimore, MD

  6. 6

    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD

  7. 7

    Department of Internal Medicine, University of Texas Medical Branch, Austin, TX

  1. †

    Fax: +1-410-614-2632.

*Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, 615 N. Wolfe St., Rm. E 6132A, Baltimore, MD 21205, USA

Publication History

  1. Issue published online: 17 JUN 2008
  2. Article first published online: 4 JUN 2008
  3. Manuscript Accepted: 22 FEB 2008
  4. Manuscript Received: 4 JAN 2008

Funded by

  • American Institute for Cancer Research
  • Maryland Cigarette Restitution Fund at Johns Hopkins University
  • Fulbright
  • Hellenic State Scholarships Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (295K)

References

  • 1
    Pepys MB. CRP or not CRP? That is the question. Arterioscler Thromb Vasc Biol 2005; 25: 1091–4.
  • 2
    Gabay C,Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448–54.
  • 3
    Gan WQ,Man SF,Senthilselvan A,Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574–80.
  • 4
    Otterness IG. The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum 1994; 24: 91–104.
  • 5
    Bruce WR,Giacca A,Medline A. Possible mechanisms relating diet and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 1271–9.
  • 6
    Dymicka-Piekarska V,Matowicka-Karna J,Gryko M,Kemona-Chetnik I,Kemona H. Relationship between soluble P-selectin and inflammatory factors (interleukin-6 and C-reactive protein) in colorectal cancer. Thromb Res 2007; 120: 585–90.
  • 7
    Engwegen JY,Helgason HH,Cats A,Harris N,Bonfrer JM,Schellens JH,Beijnen JH. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol 2006; 12: 1536–44.
  • 8
    McMillan DC,Talwar D,Sattar N,Underwood M,O'Reilly DS,McArdle C. The relationship between reduced vitamin antioxidant concentrations and the systemic inflammatory response in patients with common solid tumours. Clin Nutr 2002; 21: 161–4.
  • 9
    Zaloudik J,Lauerova L,Janakova L,Talac R,Simickova M,Nekulova M,Mikulikova I,Kovarik J,Sheard M. Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver. Hepatogastroenterology 1999; 46: 220–7.
  • 10
    Rifai N,Buring JE,Lee IM,Manson JE,Ridker PM. Is C-reactive protein specific for vascular disease in women? Ann Intern Med 2002; 136: 529–33.
  • 11
    Zhang SM,Buring JE,Lee IM,Cook NR,Ridker PM. C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med 2005; 142: 425–32.
  • 12
    Erlinger TP,Platz EA,Rifai N,Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004; 291: 585–90.
  • 13
    Gunter MJ,Stolzenberg-Solomon R,Cross AJ,Leitzmann MF,Weinstein S,Wood RJ,Virtamo J,Taylor PR,Albanes D,Sinha R. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 2006; 66: 2483–7.
  • 14
    Il'yasova D,Colbert LH,Harris TB,Newman AB,Bauer DC,Satterfield S,Kritchevsky SB. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005; 14: 2413–18.
  • 15
    Ito Y,Suzuki K,Tamakoshi K,Wakai K,Kojima M,Ozasa K,Watanabe Y,Kawado M,Hashimoto S,Suzuki S,Tokudome S,Toyoshima H, et al. Colorectal cancer and serum C-reactive protein levels: a case-control study nested in the JACC Study. J Epidemiol 2005; 15: S185–9.
  • 16
    Otani T,Iwasaki M,Sasazuki S,Inoue M,Tsugane S. Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev 2006; 15: 690–5.
  • 17
    Siemes C,Visser LE,Coebergh JW,Splinter TA,Witteman JC,Uitterlinden AG,Hofman A,Pols HA,Stricker BH. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 2006; 24: 5216–22.
  • 18
    Trichopoulos D,Psaltopoulou T,Orfanos P,Trichopoulou A,Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 2006; 15: 381–4.
  • 19
    von Elm E,Altman DG,Egger M,Pocock SJ,Gotzsche PC,Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007; 147: 573–7.
  • 20
    Greenland S,Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992; 135: 1301–9.
  • 21
    Orsini N,Bellocco R,Greenland S. Generalized least squares for trend estimation of summarized dose-response data. Stata J 2006; 6: 40–57.
  • 22
    DerSimonian R,Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–88.
  • 23
    Egger M,Davey Smith G,Schneider M,Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–34.
  • 24
    Begg CB,Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088–101.
  • 25
    Heikkila K,Ebrahim S,Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 2007; 61: 824–33.
  • 26
    Kim S,Keku TO,Martin C,Galanko J,Woosley JT,Schroeder JC,Satia JA,Halabi S,Sandler RS. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res 2008; 68: 323–8.
  • 27
    Ognjanovic S,Yamamoto J,Salzman B,Franke A,Le Marchand L. The relationships of serum CRP and IL-6 levels with lifestyle factors, race/ethinity and colorectal adenoma risk. In: Proceedings of the American Association for Cancer Research, April 2006, Washington, DC.
  • 28
    Tsilidis KK,Erlinger TP,Rifai N,Hoffman S,Hoffman-Bolton J,Helzlsouer KJ,Platz EA. C-reactive protein and colorectal adenoma in the CLUE II cohort. Cancer Causes Control 2008; Jan 24 [Electronic publication ahead of print].
  • 29
    Corpet DE,Pierre F. Point: from animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003; 12: 391–400.
  • 30
    Corpet DE,Tache S. Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 2002; 43: 1–21.
  • 31
    Itzkowitz SH,Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004; 287: G7–17.
  • 32
    Cooper HS,Murthy S,Kido K,Yoshitake H,Flanigan A. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis 2000; 21: 757–68.
  • 33
    Okayasu I,Yamada M,Mikami T,Yoshida T,Kanno J,Ohkusa T. Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model. J Gastroenterol Hepatol 2002; 17: 1078–83.
    Direct Link:
  • 34
    Danesh J,Lewington S,Thompson SG,Lowe GD,Collins R,Kostis JB,Wilson AC,Folsom AR,Wu K,Benderly M,Goldbourt U,Willeit J, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005; 294: 1799–809.
  • 35
    Gunter MJ,Canzian F,Landi S,Chanock SJ,Sinha R,Rothman N. Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2006; 15: 1126–31.
  • 36
    Ko WF,Helzlsouer KJ,Comstock GW. Serum albumin, bilirubin, and uric acid and the anatomic site-specific incidence of colon cancer. J Natl Cancer Inst 1994; 86: 1874–5.
  • 37
    Landi S,Moreno V,Gioia-Patricola L,Guino E,Navarro M,de Oca J,Capella G,Canzian F. Association of common polymorphisms in inflammatory genes interleukin (IL)6. IL8, tumor necrosis factor alpha. NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 2003; 63: 3560–6.
  • 38
    Lee YJ,Lee HR,Nam CM,Hwang UK,Jee SH. White blood cell count and the risk of colon cancer. Yonsei Med J 2006; 47: 646–56.
  • 39
    Theodoropoulos G,Papaconstantinou I,Felekouras E,Nikiteas N,Karakitsos P,Panoussopoulos D,Lazaris ACh,Patsouris E,Bramis J,Gazouli M. Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol 2006; 12: 5037–43.
  • 40
    Itzkowitz SH. Cancer prevention in patients with inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 1133–44.
  • 41
    Arber N,Eagle CJ,Spicak J,Racz I,Dite P,Hajer J,Zavoral M,Lechuga MJ,Gerletti P,Tang J,Rosenstein RB,Macdonald K, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355: 885–95.
  • 42
    Benamouzig R,Deyra J,Martin A,Girard B,Jullian E,Piednoir B,Couturier D,Coste T,Little J,Chaussade S. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003; 125: 328–36.
  • 43
    Bertagnolli MM,Eagle CJ,Zauber AG,Redston M,Solomon SD,Kim K,Tang J,Rosenstein RB,Wittes J,Corle D,Hess TM,Woloj GM, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 873–84.
  • 44
    Rosenberg L,Palmer JR,Zauber AG,Warshauer ME,Stolley PD,Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991; 83: 355–8.
  • 45
    Davey Smith G,Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003; 32: 1–22.
View Full Article (HTML) Get PDF (295K)